US FDA approves Novartis's version of Betaseron
This article was originally published in Scrip
Executive Summary
The US FDA has approved Novartis's Extavia (interferon beta-1b), an identical product to Bayer's Betaseron, for the treatment of relapsing–remitting multiple sclerosis to reduce the frequency of clinical exacerbations. It is also approved for patients who have experienced a first clinical episode of MS and have features consistent with MS as shown by MRI.